Galecto’s founders have pioneered the scientific exploration of galectin biology and chemistry.

Hans SchambyeCEO

Galectins represent a promising new drug-target. Galecto’s modulators may open up new treatment possibilities for many severe diseases.

Hakon LefflerProfessor, Lund University, Department of Laboratory Medicine

Galectin-3 plays a key role in fibrosis development and Galecto’s inhibitors are able to potently block this effect, and may thus lend new hope to patients suffering from fibrosis.

Tariq Sethi